Previous studies determined the upregulation of genes related to immune cell activation (e.g., CD3D, CD8, CXCR3, CCL5, CXCL9, and CXCL10) in cancer patients with a better prognosis [36–38], thereby highlighting the impacts of immune-related genes on tumor progression. This evidence concerns the gene CXCL9 and neoplasm.